Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

Stopped early · Phase 3 · Has a placebo group

Conditions studied: Nonalcoholic Steatohepatitis

In brief

The primary objective of this study is to evaluate whether selonsertib (SEL; GS-4997) can cause fibrosis regression and reduce associated complications in adults with cirrhosis due to NASH.

Key facts

Study ID
NCT03053063
Run by
Gilead Sciences
People needed
883
Starts
2017-01-30
Expected to finish
2019-05-06
Last updated by the study team
2020-05-07

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.